CATXNYSEPharmaceutical PreparationsFiscal year ends December 31
Perspective Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.19+0.02 (+0.92%)
Close on Oct 19, 2026
- Market cap
- $264.23M
- P/E (TTM)
- –
- Dividend yield
- –
Perspective Therapeutics, Inc. revenue by segment
By business segment
| Revenue | Q4 22 | Q3 22 | % of revenue |
|---|---|---|---|
| Brachytherapy Segment [Member] | $2.51M | $2.91M | 100.0% |
| Drug Operations Segment [Member] | $0 | $0 | 0.0% |
| Operating income | Q4 22 | Q3 22 |
|---|---|---|
| Drug Operations Segment [Member] | $0 | $0 |
| Brachytherapy Segment [Member] | -$789.00K | -$56.00K |
By product or service
By region
From the segment and revenue-disaggregation notes of Perspective Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.